Literature DB >> 26013206

National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall Survival.

Yoshiaki Murakami1, Sohei Satoi, Masayuki Sho, Fuyuhiko Motoi, Ippei Matsumoto, Manabu Kawai, Goro Honda, Kenichiro Uemura, Hiroaki Yanagimoto, Makoto Shinzeki, Masanao Kurata, Shoichi Kinoshita, Hiroki Yamaue, Michiaki Unno.   

Abstract

BACKGROUND: The aim of this study was to evaluate the validity of preoperative resectability status, as defined by the National Comprehensive Cancer Network (NCCN), from the viewpoint of overall survival.
METHODS: A total of consecutive 704 patients with pancreatic head carcinoma who underwent pancreatoduodenectomy with upfront surgery at seven Japanese hospitals between 2001 and 2012 were evaluated retrospectively. According to the NCCN definition of preoperative resectability status, tumors were divided into resectable tumors without vascular contact (R group), resectable tumors with portal or superior mesenteric vein (PV/SMV) contact of ≦180° (R-PV group), borderline resectable(BR) tumors with PV/SMV contact of >180° (BR-PV group), and BR tumors with arterial contact (BR-A group). The relationship between the NCCN definition of preoperative resectability status and overall survival was analyzed.
RESULTS: Of the 704 patients, 389, 114, 145, and 56 were classified into the R group, the R-PV group, the BR-PV group, and the BR-A group, respectively. Overall survival of the BR-PV and BR-A groups was significantly worse than that of the R group and R-PV groups (P < 0.05), although there was no significant difference in overall survival between the R group and the R-PV group (P = 0.310). Multivariate analysis revealed that PV/SMV contact of >180° (P = 0.008) and arterial contact (P < 0.001) were independent prognostic factors of overall survival.
CONCLUSION: From the viewpoint of overall survival, the NCCN definition of preoperative resectability status was valid.

Entities:  

Mesh:

Year:  2015        PMID: 26013206     DOI: 10.1007/s00268-015-3096-3

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  Indications and techniques of extended resection for pancreatic cancer.

Authors:  Akimasa Nakao; Shin Takeda; Soichiro Inoue; Shuji Nomoto; Naohito Kanazumi; Hiroyuki Sugimoto; Tsutomu Fujii
Journal:  World J Surg       Date:  2006-06       Impact factor: 3.352

2.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

3.  Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.

Authors:  Shinichiro Takahashi; Taira Kinoshita; Masaru Konishi; Naoto Gotohda; Yuichiro Kato; Takahiro Kinoshita; Tatsushi Kobayashi; Syuichi Mitsunaga; Kohei Nakachi; Masafumi Ikeda
Journal:  J Hepatobiliary Pancreat Sci       Date:  2011-07       Impact factor: 7.027

4.  NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.

Authors:  Klaus Sahora; Irene Kuehrer; Axel Eisenhut; Belgin Akan; Claus Koellblinger; Peter Goetzinger; Bela Teleky; Raimund Jakesz; Markus Peck-Radosavljevic; Ahmed Ba'ssalamah; Christoph Zielinski; Michael Gnant
Journal:  Surgery       Date:  2010-09-06       Impact factor: 3.982

5.  Borderline resectable/locally advanced pancreatic adenocarcinoma: improvements needed in population-based registries.

Authors:  John T Miura; Douglas B Evans; Sam G Pappas; T Clark Gamblin; Kiran K Turaga
Journal:  Ann Surg Oncol       Date:  2013-09-04       Impact factor: 5.344

6.  Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.

Authors:  Jae-Lyun Lee; Song Cheol Kim; Ji-Hoon Kim; Sang Soo Lee; Tae-Won Kim; Do Hyun Park; Dong Wan Seo; Sung Koo Lee; Myung-Hwan Kim; Jong Hoon Kim; Jin-Hong Park; Sang Hyun Shin; Duck Jong Han
Journal:  Surgery       Date:  2012-06-06       Impact factor: 3.982

7.  Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Naoya Nakagawa; Taijiro Sueda
Journal:  J Surg Oncol       Date:  2012-02-13       Impact factor: 3.454

8.  Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

9.  Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery.

Authors:  Hiroyuki Kato; Masanobu Usui; Shuji Isaji; Takukazu Nagakawa; Keita Wada; Michiaki Unno; Akimasa Nakao; Shuichi Miyakawa; Tetsuo Ohta
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-08       Impact factor: 7.027

10.  Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection.

Authors:  Yuji Kaneoka; Akihiro Yamaguchi; Masatoshi Isogai
Journal:  Surgery       Date:  2009-02-23       Impact factor: 3.982

View more
  6 in total

1.  MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.

Authors:  Jae Seok Bae; Jung Hoon Kim; Ijin Joo; Won Chang; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

Review 2.  Use of imaging as staging and surgical planning for pancreatic surgery.

Authors:  Andrew Hieu Nguyen; Laleh G Melstrom
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

Review 3.  Pancreatic Cancer from Molecular Pathways to Treatment Opinion.

Authors:  Michail Karanikas; Agis Esempidis; Zeinep Tzoutze Memet Chasan; Theodora Deftereou; Maria Antonopoulou; Ferdi Bozali; Kyriakos Amarantidis; Yan-Gao Man
Journal:  J Cancer       Date:  2016-06-25       Impact factor: 4.207

Review 4.  Neoadjuvant therapy for resectable pancreatic cancer.

Authors:  Sheikh Hasibur Rahman; Robin Urquhart; Michele Molinari
Journal:  World J Gastrointest Oncol       Date:  2017-12-15

5.  Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer.

Authors:  Y Kishi; S Nara; M Esaki; N Hiraoka; K Shimada
Journal:  BJS Open       Date:  2019-01-24

6.  Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.

Authors:  Takahiro Einama; Hirofumi Kamachi; Yosuke Tsuruga; Toshihiro Sakata; Kazuaki Shibuya; Yuzuru Sakamoto; Shingo Shimada; Kenji Wakayama; Tatsuya Orimo; Hideki Yokoo; Toshiya Kamiyama; Norio Katoh; Yusuke Uchinami; Tomoko Mitsuhashi; Akinobu Taketomi
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.